EyePoint Pharmaceuticals, Inc.
EYPTNASDAQHealthcare● Active
$11.78
$-0.48(-3.92%)
Market Cap$987650490
P/E Ratio—
52W High$19.11
52W Low$7.94
EyePoint Pharmaceuticals, Inc. (EYPT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
EYPT · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 6, 2026EPS Actual
-$0.99
Est. -$0.79 · -25.3%
Revenue
$0.00B
Est. $0.00B · +97.3%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 6, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
EYPT reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.07
Rev. $15.39B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.07
Rev. Est.$15.39B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | -$0.94 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 6, 2026 | -$0.79 | -$0.99 | -25.3% | $0.00B | $0.00B | +97.3% |
| ▼ Q1 FY2026 | Mar 4, 2026 | -$0.78 | -$0.81 | -3.9% | $0.00B | $0.00B | -37.6% |
| ▼ Q4 FY2025 | Nov 5, 2025 | -$0.77 | -$0.85 | -10.4% | $0.00B | $0.00B | -4.0% |
| ▼ Q3 FY2025 | Aug 6, 2025 | -$0.67 | -$0.85 | -26.9% | $0.01B | $0.00B | +29.2% |
| — Q2 FY2025 | May 7, 2025 | -$0.65 | -$0.65 | +0.0% | $0.02B | $0.01B | +258.4% |
| ▼ Q1 FY2025 | Mar 5, 2025 | -$0.54 | -$0.64 | -18.5% | $0.01B | $0.01B | +41.5% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -$0.48 | -$0.54 | -12.5% | $0.01B | $0.01B | -0.3% |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
-$0.94
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 6, 2026Miss
EPS Actual
-$0.99
EPS Est.
-$0.79
EPS Surpr.
-25.3%
Revenue
$0.00B
Q1 FY2026
Mar 4, 2026Miss
EPS Actual
-$0.81
EPS Est.
-$0.78
EPS Surpr.
-3.9%
Revenue
$0.00B
Q4 FY2025
Nov 5, 2025Miss
EPS Actual
-$0.85
EPS Est.
-$0.77
EPS Surpr.
-10.4%
Revenue
$0.00B
Q3 FY2025
Aug 6, 2025Miss
EPS Actual
-$0.85
EPS Est.
-$0.67
EPS Surpr.
-26.9%
Revenue
$0.01B
Q2 FY2025
May 7, 2025
EPS Actual
-$0.65
EPS Est.
-$0.65
EPS Surpr.
+0.0%
Revenue
$0.02B
Q1 FY2025
Mar 5, 2025Miss
EPS Actual
-$0.64
EPS Est.
-$0.54
EPS Surpr.
-18.5%
Revenue
$0.01B
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
-$0.54
EPS Est.
-$0.48
EPS Surpr.
-12.5%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.64 | $-0.64 | $-0.64 | 2 |
| Q3 FY2027 | $-0.64 | $-0.64 | $-0.64 | 2 |
| Q2 FY2027 | $-0.65 | $-0.65 | $-0.65 | 2 |
| Q1 FY2027 | $-0.65 | $-0.65 | $-0.65 | 2 |
| Q4 FY2026 | $-0.82 | $-0.82 | $-0.82 | 4 |
| Q3 FY2026 | $-1.00 | $-0.81 | $-0.56 | 6 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 5 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 6 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 6, 2026 | -25.3% | $13.75 | $13.35 | -2.91% |
| ▼ Q1 FY2026 | Mar 4, 2026 | -3.9% | $18.32 | $18.00 | -1.75% |
| ▼ Q4 FY2025 | Nov 5, 2025 | -10.4% | $12.39 | $11.02 | -11.06% |
| ▼ Q3 FY2025 | Aug 6, 2025 | -26.9% | $10.89 | $10.58 | -2.85% |
| ▲ Q2 FY2025 | May 7, 2025 | +0.0% | $6.25 | $6.09 | -2.56% |
| ▼ Q1 FY2025 | Mar 5, 2025 | -18.5% | $6.08 | $6.58 | +8.22% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -12.5% | $12.08 | $11.59 | -4.06% |
| ▼ Q3 FY2024 | Aug 7, 2024 | -5.5% | $9.02 | $8.65 | -4.10% |
Q2 FY2026-2.91%
Report Date
May 6, 2026
EPS Beat/Miss
-25.3%
Price Before
$13.75
Price After
$13.35
Q1 FY2026-1.75%
Report Date
Mar 4, 2026
EPS Beat/Miss
-3.9%
Price Before
$18.32
Price After
$18.00
Q4 FY2025-11.06%
Report Date
Nov 5, 2025
EPS Beat/Miss
-10.4%
Price Before
$12.39
Price After
$11.02
Q3 FY2025-2.85%
Report Date
Aug 6, 2025
EPS Beat/Miss
-26.9%
Price Before
$10.89
Price After
$10.58
Q2 FY2025-2.56%
Report Date
May 7, 2025
EPS Beat/Miss
+0.0%
Price Before
$6.25
Price After
$6.09
Q1 FY2025+8.22%
Report Date
Mar 5, 2025
EPS Beat/Miss
-18.5%
Price Before
$6.08
Price After
$6.58
Q4 FY2024-4.06%
Report Date
Nov 7, 2024
EPS Beat/Miss
-12.5%
Price Before
$12.08
Price After
$11.59
Q3 FY2024-4.10%
Report Date
Aug 7, 2024
EPS Beat/Miss
-5.5%
Price Before
$9.02
Price After
$8.65
Avg Beat Reaction-2.56%
Avg Miss Reaction-2.64%
Beat Rate1 / 8 quarters
Largest Move-11.06% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: EYPT ends December
EyePoint Pharmaceuticals, Inc. (EYPT) most recently reported earnings on May 6, 2026 for Q2 FY2026, posting EPS of $-0.99 — missing the analyst consensus of $-0.79 by -25.3%. The next EYPT earnings date is expected around September 1, 2026.
Each quarter, investors track EYPT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. EYPT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
EYPT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
EYPT earnings · 5 questionsEyePoint Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. EYPT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; EYPT historically reports after market close (AMC).
EYPT earnings datewhen is EYPT earningsEYPT next earnings datewhen does EYPT report earningsEYPT earnings calendar
▸ Source: FMP · EyePoint Pharmaceuticals, Inc. SEC filings · US GAAP · EyePoint Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026